TickerTalks
Browse all tickers →
TickerTalks›$PRCT
PRPRCT

PROCEPT BioRobotics Corporation

$PRCT·$1.2B·Medical - Devices·Healthcare
$21.03-10.4%YTD-33.6%1Y-63.7%
Mentions · last 7 days
2026-06-27: 0 posts2026-06-28: 3 posts2026-06-29: 2 posts2026-06-30: 3 posts2026-07-01: 3 posts2026-07-02: 3 posts2026-07-03: 3 posts18
Price updated 1d ago·X counts updated 33m ago
PRPRCT
$PRCTPROCEPT BioRobotics Corporation
$21.03-10.40%18 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $PRCT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-07-04

Falling on heavy selling — points lower unless it turns around.

PROCEPT BioRobotics down 64% in a year — dropped 10% today, 4% of 52-week range, Aquablation adoption is the whole thesis.

PROCEPT BioRobotics develops surgical robotic systems for urological procedures, primarily Aquablation therapy for BPH. The stock is down 64% over twelve months at 4% of the 52-week range and dropped 10% today.

  • The revenue side is real but decelerating: Q1 revenue of $83 million grew 20% year-over-year with Q4 2025 growing 12% — that's real but the deceleration is the specific concern.
  • The AUA Guidelines Strengthening is a specific clinical positive: AUA Guidelines Strengthen Recommendation for Aquablation Therapy on May 14 — that's the specific clinical-society support for the commercial thesis.
  • The WATER IV Study Enrollment Completion adds pipeline expansion: PROCEPT BioRobotics Advances Prostate Cancer Program with WATER IV Study Enrollment Completion — that's specific pipeline extension into a new oncology indication.
  • The valuation is stretched relative to the tape: 3.7x sales for a business at -34% operating margin — the multiple assumes continued commercial acceleration that isn't materializing.

The August 5 print is the near-term test — a return to 20%+ revenue growth plus specific commentary on the WATER IV timeline and international expansion is what could arrest the breakdown. A specific revenue miss or Aquablation adoption plateau is what confirms today's breakdown extends into a real de-rating.

What to watch: August 5 Q2 earnings. A return to 20%+ revenue growth plus WATER IV timeline and international expansion commentary could arrest the breakdown; a specific revenue miss or Aquablation adoption plateau extends today's breakdown.

On the calendar: 2026-08-05 — Q2 2026 earnings

Read the AI verdict + X sentiment for $PRCT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $PRCT.

Medical - Devices · Healthcare

Robotic surgery is the durable secular driver — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures. FDA regulatory acceleration for robotic platforms and emerging non-invasive alternatives (Butterfly Network ultrasound) are secondary structural themes broadening the device innovation landscape.

Industry benchmark

12-name peer basket
-1.1%YTD
+13.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-25.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-33.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-27.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
63.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$-0.56$-0.55-1.8%
Q4 2025Feb 25, 2026$-0.53$-0.32-65.6%
Q3 2025Nov 4, 2025$-0.38$-0.41+7.3%
Q2 2025Aug 6, 2025$-0.35$-0.41+14.6%
Next earningsWed, Aug 5·consensus EPS $-0.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$83.1M+20.2%64.9%-39.2%$-0.56$-41.0M
Q4 FY25$76.4M+11.9%60.6%-40.6%$-0.53$-12.2M
Q3 FY25$83.3M+42.8%62.9%-27.8%$-0.38$-9.5M
Q2 FY25$79.2M+48.4%63.3%-28.0%$-0.35$-17.8M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$398.0M$393.2M – $404.0M-$1.54-$1.67 – -$1.449
FY27$490.8M$485.9M – $495.7M-$0.92-$1.41 – -$0.619
FY28$586.7M$586.5M – $587.0M-$0.64-$1.22 – -$0.356
FY29$678.7M$666.5M – $688.4M-$0.33-$0.33 – -$0.325
FY30$794.9M$780.6M – $806.2M$0.64$0.63 – $0.653

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.4%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-28.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 54.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.855-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 8Alaleh NouriEVP, CLO, CORP. SEC.285 sh$8KSellJun 8Kevin WatersCFO357 sh$10KSellJun 8Barry L TemplinCTO358 sh$10KSellMar 19Alaleh NouriEVP, CLO, CORP. SEC.5.4K sh$139KSellMar 17Alaleh NouriEVP, CLO, CORP. SEC.304 sh$9KSellMar 17Kevin WatersCFO706 sh$20KSellMar 10Alaleh NouriEVP, CLO, CORP. SEC.3.2K sh$83KBuyMar 9Desai Antal RohitDirector98.7K sh$2.4MBuyMar 6Desai Antal RohitDirector160.3K sh$3.8MSellMar 6Alaleh NouriEVP, CLO, CORP. SEC.6.9K sh$163K
1–10 of 11
+ 11 other (11 awards) in window

See when $PRCT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
3New insider — initial holdingsApr 303
3New insider — initial holdingsApr 243
3New insider — initial holdingsMar 93
8-KOfficer or director changeMar 68-K — Item 5.02: Officer or director change
8-KPress release / Reg FDFeb 268-K — Item 7.01: Press release / Reg FD
+ 15 other (7 13Gs · 2 earnings 8-Ks · 2 proxys · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More247wallst.com·24d agoPROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approvalglobenewswire.com·38d agoAUA Guidelines Strengthen Recommendation for Aquablation® Therapyglobenewswire.com·52d agoPROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·53d agoPROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & Juneglobenewswire.com·65d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BIO$TMDX$ABT$ISRG$BSX$BFLY$ECOR$NNOX
Voices on X · last 7 days

No standout posts about $PRCT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport